1. Home
  2. RGLS vs OPRT Comparison

RGLS vs OPRT Comparison

Compare RGLS & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • OPRT
  • Stock Information
  • Founded
  • RGLS 2007
  • OPRT 2005
  • Country
  • RGLS United States
  • OPRT United States
  • Employees
  • RGLS N/A
  • OPRT N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • OPRT Finance: Consumer Services
  • Sector
  • RGLS Health Care
  • OPRT Finance
  • Exchange
  • RGLS Nasdaq
  • OPRT Nasdaq
  • Market Cap
  • RGLS 102.1M
  • OPRT 110.7M
  • IPO Year
  • RGLS 2012
  • OPRT 2019
  • Fundamental
  • Price
  • RGLS $1.42
  • OPRT $3.15
  • Analyst Decision
  • RGLS Strong Buy
  • OPRT Buy
  • Analyst Count
  • RGLS 6
  • OPRT 4
  • Target Price
  • RGLS $10.33
  • OPRT $5.17
  • AVG Volume (30 Days)
  • RGLS 493.3K
  • OPRT 153.9K
  • Earning Date
  • RGLS 11-07-2024
  • OPRT 11-12-2024
  • Dividend Yield
  • RGLS N/A
  • OPRT N/A
  • EPS Growth
  • RGLS N/A
  • OPRT N/A
  • EPS
  • RGLS N/A
  • OPRT N/A
  • Revenue
  • RGLS N/A
  • OPRT $796,991,000.00
  • Revenue This Year
  • RGLS N/A
  • OPRT N/A
  • Revenue Next Year
  • RGLS N/A
  • OPRT $5.58
  • P/E Ratio
  • RGLS N/A
  • OPRT N/A
  • Revenue Growth
  • RGLS N/A
  • OPRT N/A
  • 52 Week Low
  • RGLS $1.08
  • OPRT $2.05
  • 52 Week High
  • RGLS $3.79
  • OPRT $4.60
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 41.95
  • OPRT 55.54
  • Support Level
  • RGLS $1.36
  • OPRT $3.00
  • Resistance Level
  • RGLS $1.65
  • OPRT $3.28
  • Average True Range (ATR)
  • RGLS 0.10
  • OPRT 0.19
  • MACD
  • RGLS -0.01
  • OPRT 0.01
  • Stochastic Oscillator
  • RGLS 28.57
  • OPRT 58.39

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: